SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01004497
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      The main aim of the present study is to evaluate the clinical efficacy of first-line
      dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic
      leukemia. In this study, the investigators will analyze the clinical outcomes for entire
      patient population as well as those for transplants, respectively. In addition, the results
      of this study will be compared to those of the investigators current study (imatinib plus
      conventional chemotherapy). The safety of this treatment will also be studied.
    
Name: Dasatinib
Description: After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
 Name: Cyclophosphamide
Description: 300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
 Name: Vincristine
Description: 1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
 Name: Daunorubicin
Description: 45 mg/m2/day, IV for 1 hour, days 4 & 11
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
 Name: Dexamethasone
Description: 40 mg/day, IV push, days 1-4 & days 11-14
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
 Name: Cytarabine
Description: 2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
 Type: Drug
Group Labels:  2  Modified Hyper-CVAD  Modified Hyper-CVAD + Dasatinib  
 Name: Mitoxantrone
Description: 12 mg/m2/day, IV for 30 minutes, days 1-2
 Type: Drug
Group Labels:  1  Modified Hyper-CVAD + Dasatinib  
  
Primary Outcomes 
 Measure: To determine the clinical efficacy of dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive ALL in terms of major molecular response rate Time: by the second 4-week dasatinib therapy
   
Secondary Outcomes 
 Measure: To evaluate the long-term clinical outcomes (including transplant outcomes) in terms of treatment toxicity, relapse, disease-free survival, and overall survival Time: at 2 years after transplantation (for all transplants); at 2 years after starting dasatinib maintenance (for all non-transplants)
 
Purpose: Treatment
Allocation: N/A
Single Group Assignment 
There is one SNP
SNPs
1 T315I 
Dasatinib, a potent dual BCR-ABL/SRC family kinase inhibitor, demonstrated 325-fold greater
      activity against native BCR-ABL compared with imatinib and has shown efficacy against all
      imatinib-resistant BCR-ABL mutations with the exception of T315I. --- T315I ---